|
Advantage of AH-601-AMD:
|
|
|
|
|
|
1.
|
AH-601-AMD can enhance the phagocytic activity of Retinal pigment epithelial cells, and showed effective in a dry AMD mice model. So far, no dry AMD drug candidate go through this cellular mechanism.
|
|
2.
|
AH-601-AMD as an endogenous EPO inducer in retinal pigment epithelial cells, and also activate mitochondrial biogenesis and hemoglobin production in RPE cells for supplying energy and oxygen inside the RPE cells.
|
|
3.
|
Dry AMD is still a large unmet medical need that might have 10 folds market value comparing to wet form AMD.
|
|
|
|
| Sodium Iodate Disrupted the Mitochondrial-Lysosomal Axis in Cultured Retinal Pigment Epithelial Cells. | ||
|
Ying-Cheng Lin, Lin-Yea Horng Hui-Ching Sung, and Rong-Tsun Wu
Journal of ocular pharmacology and therapeutics. 34 (7): Sep 1, 2018.
|
||
|
|
|
|
|
|
|
|
|
Functions:
|
||
|
>
|
Light absorption :
|
 |
|
>
|
Transepithelial transport :
|
|
|
>
|
Ions buffering :
|
|
|
>
|
Visual cycle :
|
|
|
>
|
Phagocytosis :
|
|
|
>
|
Secretion :
|
|
|
>
|
blood–retina barrier :
|
|
|
|
Physiol Rev (2005)
|
|
|
Global market for age-related macular degeneration (AMD)
|
|
|
|
|
|
Global Data Healthcare 2018/04/05
Pharmaceutical sales within the age-related macular degeneration (AMD) markets were estimated to be $4.9bn across the seven major markets (7MM*) in 2016. This is expected to reach $11.5bn in 2026, at an impressive Compound Annual Growth Rate (CAGR) of 8.9%.
|
|
|
|
|
|
Nature Reviews Drug Discovery 12:501, 2013
Dry AMD, which in advanced forms involves atrophy of the retinal pigment epithelium (RPE) and photoreceptor cells, accounts for 90% of all AMD cases, and there are no specific drugs on the market.
|
|
|
|
|
|
Developments in Ophthalmology. 55:112-24, 2016
Nonneovascular Age-Related Macular Degeneration:
There is clearly a large unmet medical need for new therapeutic options for nonneovascular AMD.
|
|